share_log

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

中进医疗 | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/07/27 04:14

Moomoo AI 已提取核心信息

Jin Medical International reported revenue of $10.6M for H1 FY2024, up 3% YoY, while net income declined 3.5% to $1.7M. Wheelchair sales decreased 8.2% to $7.7M due to Japanese Yen weakness, while wheelchair components and other products revenue surged 52.9% to $2.9M driven by new product launches.Gross profit increased 5.8% to $3.7M with margin expanding to 35.4% from 34.4%, benefiting from higher-margin new products. Operating expenses rose 42.5% to $2.5M primarily due to increased professional fees post-IPO and expenses from newly incorporated subsidiary. Operating income declined 30.6% to $1.2M.The company maintained strong liquidity with $8.9M cash and $17.1M in short-term investments as of March 31, 2024. Management expects current cash flows, bank borrowings and IPO proceeds will be sufficient to meet working capital needs. The company continues to focus on expanding dealer networks and launching new products despite market uncertainties.
Jin Medical International reported revenue of $10.6M for H1 FY2024, up 3% YoY, while net income declined 3.5% to $1.7M. Wheelchair sales decreased 8.2% to $7.7M due to Japanese Yen weakness, while wheelchair components and other products revenue surged 52.9% to $2.9M driven by new product launches.Gross profit increased 5.8% to $3.7M with margin expanding to 35.4% from 34.4%, benefiting from higher-margin new products. Operating expenses rose 42.5% to $2.5M primarily due to increased professional fees post-IPO and expenses from newly incorporated subsidiary. Operating income declined 30.6% to $1.2M.The company maintained strong liquidity with $8.9M cash and $17.1M in short-term investments as of March 31, 2024. Management expects current cash flows, bank borrowings and IPO proceeds will be sufficient to meet working capital needs. The company continues to focus on expanding dealer networks and launching new products despite market uncertainties.
中进医疗国际报告2024财年上半年营业收入为1060万，较去年同期增长3%，而净利润下降3.5%至170万。由于日币贬值，轮椅销售下降8.2%至770万，而轮椅元件和其他产品的营业收入则因新产品发布而激增52.9%至290万。毛利润增长5.8%至370万，毛利率从34.4%扩大至35.4%，受益于新产品的高毛利。营业费用主要因IPO后专业费用增加和新成立子公司的费用上升而上升42.5%至250万。营业收入下降30.6%至120万。截至2024年3月31日，公司保持强劲的流动性，现金为890万，短期投资为1710万。管理层预计当前的现金流、银行借款和IPO收益将足以满足营运资金需求。尽管市场不确定性，公司仍继续专注于扩大经销商网络和推出新产品。
中进医疗国际报告2024财年上半年营业收入为1060万，较去年同期增长3%，而净利润下降3.5%至170万。由于日币贬值，轮椅销售下降8.2%至770万，而轮椅元件和其他产品的营业收入则因新产品发布而激增52.9%至290万。毛利润增长5.8%至370万，毛利率从34.4%扩大至35.4%，受益于新产品的高毛利。营业费用主要因IPO后专业费用增加和新成立子公司的费用上升而上升42.5%至250万。营业收入下降30.6%至120万。截至2024年3月31日，公司保持强劲的流动性，现金为890万，短期投资为1710万。管理层预计当前的现金流、银行借款和IPO收益将足以满足营运资金需求。尽管市场不确定性，公司仍继续专注于扩大经销商网络和推出新产品。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Femasys
    FEMY
    -- 1.5900
    Predictive Oncology
    POAI
    -- 1.6200
    West Pharmaceutical Services
    WST
    -- 214.730
    NexGel
    NXGL
    -- 3.530
    BioNano Genomics
    BNGO
    -- 5.7600
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？